Credit Suisse Ag Oric Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.7 - $7.07 $47,908 - $125,450	-17,744 Reduced 99.9%	17 $0
Q1 2022 May 16, 2022	SELL	$4.54 - $16.1 $2,860 - $10,143	-630 Reduced 3.43%	17,761 $94,000
Q4 2021 Feb 14, 2022	BUY	$12.01 - $20.3 $26,710 - $45,147	2,224 Added 13.76%	18,391 $270,000
Q3 2021 Nov 12, 2021	BUY	$15.9 - $25.22 $48,606 - $77,097	3,057 Added 23.32%	16,167 $339,000
Q2 2021 Aug 16, 2021	SELL	$17.37 - $25.34 $108,145 - $157,766	-6,226 Reduced 32.2%	13,110 $231,000
Q1 2021 May 14, 2021	SELL	$23.67 - $36.85 $47,008 - $73,184	-1,986 Reduced 9.31%	19,336 $473,000
Q4 2020 Feb 12, 2021	BUY	$20.32 - $39.8 $433,263 - $848,615	21,322 New	21,322 $722,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.